TECH Bio-Techne
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.
Company profile
Ticker
TECH
Exchange
Website
CEO
Charles Kummeth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Denali Therapeutics • Seagen • Exelixis ...
Former names
TECHNE CORP /MN/
SEC CIK
Corporate docs
IRS number
411427402
TECH stock data
()
News
Bio-Techne And Narayana Nethralaya Collaborate On Use Of Ella For Ophthalmic Disorder Diagnostic Applications
18 May 21
Bio-Techne Provides Update On Co's AmplideX
10 May 21
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
6 May 21
Bio-Techne Q3 Adj. EPS $1.79 Beats $1.55 Estimate, Sales $243.60M Beat $228.22M Estimate
6 May 21
Earnings Scheduled For May 6, 2021
6 May 21
Press releases
Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications
18 May 21
Multisite Study Demonstrates Utility of Asuragen Kit for Identifying Variants Linked to Spinal Muscular Atrophy
10 May 21
Bio-Techne Corp. to Host Earnings Call
6 May 21
Bio-Techne Declares Dividend
6 May 21
Bio-Techne Releases Third Quarter Fiscal 2021 Results
6 May 21
Calendar
7 May 21
18 May 21
30 Jun 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Jun 20 | Jun 19 | Jun 18 | Jun 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Bio-Techne earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 May 21 | Kelderman Kim | Common Stock | Payment of exercise | Dispose F | No | No | 427.49 | 856 | 365.93K | 1,656 |
| 1 May 21 | Kelderman Kim | Common Stock | Option exercise | Aquire M | No | No | 0 | 1,667 | 0 | 2,512 |
| 1 May 21 | Kelderman Kim | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,667 | 0 | 0 |
| 1 Mar 21 | Furlow Brenda S. | Stock Options Common Stock | Grant | Aquire A | No | No | 372.44 | 10,997 | 4.1M | 10,997 |
| 16 Feb 21 | Kummeth Charles R. | Common Stock | Payment of exercise | Dispose F | No | No | 411 | 17,428 | 7.16M | 158,841 |
| 16 Feb 21 | Kummeth Charles R. | Common Stock | Option exercise | Aquire M | No | No | 94.35 | 30,000 | 2.83M | 176,269 |
| 16 Feb 21 | Kummeth Charles R. | Stock Options Common Stock | Option exercise | Dispose M | No | No | 94.35 | 30,000 | 2.83M | 36,849 |
| 12 Feb 21 | Furlow Brenda S. | Common Stock | Sell | Dispose S | No | No | 399.1165 | 3,326 | 1.33M | 6,124 |
| 12 Feb 21 | Furlow Brenda S. | Common Stock | Sell | Dispose S | No | No | 398.3954 | 6,674 | 2.66M | 9,450 |
| 12 Feb 21 | Furlow Brenda S. | Common Stock | Option exercise | Aquire M | No | No | 106.59 | 10,000 | 1.07M | 16,124 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
approved, Asuragen, cope, educating, January, outflow, sponsoring, vaccinated, vaccination, vaccine, widely
Financial reports
10-Q
2021 Q3
Quarterly report
7 May 21
10-Q
2021 Q2
Quarterly report
8 Feb 21
10-Q
2021 Q1
Quarterly report
9 Nov 20
10-K
2020 FY
Annual report
26 Aug 20
10-Q
2020 Q3
Quarterly report
11 May 20
10-Q
2020 Q2
Quarterly report
6 Feb 20
10-Q
2020 Q1
Quarterly report
6 Nov 19
10-K/A
2019 FY
Annual report (amended)
6 Nov 19
10-K/A
2019 FY
Annual report (amended)
9 Oct 19
10-K
2019 FY
Annual report
28 Aug 19
Current reports
8-K
Bio-techne Releases Third Quarter Fiscal 2021 Results
6 May 21
8-K
Bio-techne Releases Second Quarter Fiscal 2021 Results
2 Feb 21
8-K
Bio-techne Releases First Quarter Fiscal 2021 Results
5 Nov 20
8-K
Departure of Directors or Certain Officers
3 Nov 20
8-K
Bio-techne Releases Fourth Quarter Fiscal 2020 Results
4 Aug 20
8-K
Bio-techne and Kantaro Biosciences Announce Partnership to Develop and Scale Production of COVID-19 Serology Test
19 May 20
8-K
Bio-techne Releases Third Quarter Fiscal 2020 Results
30 Apr 20
8-K
Bio-techne Releases Second Quarter Fiscal 2020 Results
4 Feb 20
8-K
Bio-techne Releases First Quarter Fiscal 2020 Results
29 Oct 19
8-K
Bio-techne Releases Fourth Quarter Fiscal 2019 Results
6 Aug 19
Registration and prospectus
S-8
Registration of securities for employees
9 Nov 20
S-8
Registration of securities for employees
7 Nov 18
S-8
Registration of securities for employees
25 Oct 17
S-8
Registration of securities for employees
29 Oct 15
S-8
Registration of securities for employees
3 Nov 14
S-8
Registration of securities for employees
11 Nov 10
S-8
Registration of securities for employees
14 Nov 00
S-8
Registration of securities for employees
12 Oct 99
S-3
Shelf registration
30 Sep 98
S-8
Registration of securities for employees
5 Oct 97
Proxies
DEFA14A
Additional proxy soliciting materials
15 Sep 20
DEF 14A
Definitive proxy
15 Sep 20
DEFA14A
Additional proxy soliciting materials
9 Sep 19
DEF 14A
Definitive proxy
9 Sep 19
DEF 14A
Definitive proxy
10 Sep 18
DEFA14A
Additional proxy soliciting materials
10 Sep 18
DEF 14A
Definitive proxy
11 Sep 17
DEFA14A
Additional proxy soliciting materials
11 Sep 17
DEF 14A
Definitive proxy
12 Sep 16
DEFA14A
Additional proxy soliciting materials
12 Sep 16
Other
UPLOAD
Letter from SEC
15 Apr 21
CORRESP
Correspondence with SEC
28 Mar 21
UPLOAD
Letter from SEC
16 Mar 21
SD
Conflict minerals disclosure
29 May 20
SD
Conflict minerals disclosure
29 May 19
SD
Conflict minerals disclosure
25 May 18
UPLOAD
Letter from SEC
30 Apr 18
CORRESP
Correspondence with SEC
4 Apr 18
SD
Conflict minerals disclosure
25 May 17
UPLOAD
Letter from SEC
15 May 17
Ownership
4
BIO-TECHNE / Kim Kelderman ownership change
4 May 21
4
BIO-TECHNE / Brenda S. Furlow ownership change
3 Mar 21
4
BIO-TECHNE / Charles R. Kummeth ownership change
18 Feb 21
4
BIO-TECHNE / James Hippel ownership change
17 Feb 21
4
BIO-TECHNE / Brenda S. Furlow ownership change
17 Feb 21
4
BIO-TECHNE / Roeland Nusse ownership change
10 Feb 21
SC 13G/A
BIO-TECHNE / VANGUARD ownership change
10 Feb 21
4
BIO-TECHNE / Kim Kelderman ownership change
9 Feb 21
4
BIO-TECHNE / Norman David Eansor ownership change
9 Feb 21
SC 13G/A
BIO-TECHNE / BlackRock ownership change
26 Jan 21
Patents
APP
Utility
Hybridoma Clones, Monoclonal Antibodies to VSIG-4, and Methods of Making and Using
25 Mar 21
Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.
APP
Utility
Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
4 Feb 21
Methods of detecting multiple nucleic acid targets in single cells through indirect capture of labels to the nucleic acids are provided.
APP
Utility
Methods to Further Enhance Signal Amplification for the In Situ Detection of Nucleic Acids
4 Feb 21
The present invention relates to detection of nucleic acids and provides a composition comprising a Signal Generating Complex, wherein the composition comprises: (A) a pair of target probes (TPs), wherein a first TP of the pair of TPs comprises a nucleic acid sequence comprising two segments; (B) a pair of base PPAs comprising the first and second base PPAs, wherein the first base PPA comprises a nucleic acid sequence comprising three segments; (C) a set of extension PPAs comprising the first and second extension PPAs, wherein the first extension PPA comprises a nucleic acid sequence comprising two segments; (D) a plurality of pre-amplifiers (PAs), wherein the PAs comprise a nucleic acid sequence comprising three segments; (E) a plurality of amplifiers (AMPs), wherein the AMPs comprise a nucleic acid sequence comprising two segments; and (F) a plurality of label probes (LPs), wherein the LPs comprise a nucleic acid sequence comprising two segments.
GRANT
Utility
Methods and kits for assaying endoglycosidase activity
12 Jan 21
A method for assaying endoglycosidase activity includes providing a proteoglycan having a glycosaminoglycan chain with a non-reducing end; treating the proteoglycan with a glycosyltransferase to incorporate a carbohydrate into the non-reducing end of the glycosaminoglycan chain, wherein the carbohydrate includes a click chemistry moiety; adding a label to the proteoglycan, wherein the label includes a click chemistry moiety that reacts to the click chemistry moiety of the carbohydrate such that the label attaches to the carbohydrate to form a labeled proteoglycan; immobilizing the labeled proteoglycan on a multi-well plate, wherein the multi-well plate includes a specific anti-proteoglycan antibody for binding the labeled proteoglycan; treating the labeled proteoglycan with an endoglycosidase specific to the glycosaminoglycan chain; and detecting the labeled proteoglycan.
APP
Utility
Methods of Detecting Nucleic Acids In Individual Cells and of Identifying Rare Cells from Large Heterogeneous Cell Populations
30 Dec 20
Methods of detecting multiple nucleic acid targets in single cells through indirect capture of labels to the nucleic acids are provided.
Transcripts
2021 Q3
Earnings call transcript
9 May 21
2021 Q2
Earnings call transcript
2 Feb 21
2021 Q1
Earnings call transcript
8 Nov 20
2020 Q4
Earnings call transcript
4 Aug 20
2020 Q3
Earnings call transcript
1 May 20
2020 Q2
Earnings call transcript
4 Feb 20
2020 Q1
Earnings call transcript
29 Oct 19
2019 Q4
Earnings call transcript
6 Aug 19
2019 Q3
Earnings call transcript
30 Apr 19
2019 Q2
Earnings call transcript
5 Feb 19
Reddit threads
CNBC's Jim Cramer Is So Full of S**t...
14 May 21
Daily Discussion Thread - May 14th, 2021
14 May 21
Daily Discussion Thread - May 13th, 2021
13 May 21
Daily Discussion Thread - May 12th, 2021
12 May 21
Best Dip Stocks to buy right now
12 May 21
What happened last night? Like the whole market tanked at close
11 May 21
Buying opportunity like before April?
11 May 21
[Motley Fool] Current model for Uber, Lyft just doesn't work. Expenses have scaled up in near-perfect step with revenue, as have net losses. As it stands now, both EBITDA improvement outlooks are tough to believe.
10 May 21
What Are Your Moves Tomorrow - May 10, 2021
9 May 21
Unfazed and Resolute: ARK Supremo Cathie Wood Brushes Off Recent Pullback In Growth Stocks/SPACs, And Doubles Down..
9 May 21